Research Compound Overview

MOTS-c: The Mitochondrial-Derived Peptide — Exercise Mimetic & Metabolic Research

Last updated: March 31, 2026 · Published in Cell Metabolism & Nature Communications

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome — specifically within the 12S rRNA gene. First described in a landmark 2015 paper published in Cell Metabolism, MOTS-c was one of the first identified "mitochondrial-derived peptides" (MDPs) — bioactive signaling molecules produced by mitochondrial DNA that act as circulating hormones affecting metabolism throughout the body.

What makes MOTS-c particularly notable in current research is its characterization as an exercise-induced peptide. A 2021 study published in Nature Communications demonstrated that MOTS-c is released during physical exercise and mediates some of the metabolic benefits associated with exercise — leading to its description as a potential "exercise mimetic" in the research literature.

Chemical Profile

Discovery & Significance

Before MOTS-c's discovery, mitochondrial DNA was thought to encode only 13 proteins (all components of the electron transport chain), 22 tRNAs, and 2 rRNAs. The identification of MOTS-c and other mitochondrial-derived peptides revealed that mitochondrial DNA contains additional functional open reading frames that produce bioactive signaling molecules — fundamentally expanding our understanding of what the mitochondrial genome does.

MOTS-c functions as a mitokine — a signaling molecule produced by mitochondria that acts at a distance throughout the body, not just within the cell that produced it. This means mitochondria are not merely energy-producing organelles but also endocrine-like signaling centers that communicate metabolic status to distant tissues through circulating peptides.

Mechanism of Action

AMPK Activation

MOTS-c's primary characterized mechanism involves activation of AMPK (AMP-activated protein kinase) — the cell's master energy sensor. AMPK is activated when cellular energy is low (high AMP:ATP ratio) and triggers a cascade of metabolic adjustments: increased glucose uptake, enhanced fatty acid oxidation, stimulated mitochondrial biogenesis, and suppressed energy-consuming processes like lipogenesis.

MOTS-c activates AMPK through an indirect mechanism involving inhibition of the folate-methionine cycle. By disrupting this cycle, MOTS-c causes accumulation of the intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which is a well-established endogenous AMPK activator. This metabolic route is distinct from other AMPK activators and represents a uniquely mitochondria-derived pathway for regulating cellular energy balance.

Nuclear Translocation

Under metabolic stress conditions, MOTS-c translocates from the cytoplasm to the cell nucleus, where it directly regulates gene expression. This is a remarkable finding — a peptide encoded by mitochondrial DNA that physically moves to the nuclear genome to influence transcription. Published research shows that nuclear MOTS-c interacts with stress-responsive transcription factors, modulating the expression of genes involved in antioxidant defense and metabolic adaptation.

The Exercise Connection

The 2021 Nature Communications study demonstrated that MOTS-c is released into circulation during exercise in both mice and humans. The study showed that exercise-induced MOTS-c promotes physical capacity and that exogenous MOTS-c administration could partially replicate exercise's metabolic benefits in sedentary aged animals — hence its characterization as an "exercise mimetic."

Position in Mitochondrial Research

MOTS-c exists alongside other mitochondrial-targeted research compounds including SS-31 (Elamipretide), which stabilizes mitochondrial inner membrane structure through cardiolipin binding, and NAD+, which supports electron transport chain function and sirtuin-mediated mitochondrial quality control. While SS-31 and NAD+ address mitochondrial structure and energy production directly, MOTS-c represents the mitochondrial signaling dimension — how mitochondria communicate their status to the rest of the body.

Research Limitations

MOTS-c research is still relatively young — the foundational discovery paper was published in 2015, giving the field approximately 11 years of published literature. While the studies published to date are in high-impact journals (Cell Metabolism, Nature Communications), the total body of evidence is smaller than that for longer-established compounds like BPC-157 or GHK-Cu. Human clinical trials specifically investigating MOTS-c administration are limited, and most mechanistic data comes from cell culture and animal models.